ArticleFrontiers in oncology2026
Survival analysis and prognostic factors of mature T-cell and natural killer/T-cell neoplasms in Colombian patients from 2008-2025.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T-cell lymphomas show global variation, but research in Latin America remains limited. The main outcome This study aimed to determine, subtype distribution frequency, treatment, and overall survival of T-cell lymphoma. Methods: We conducted a retrospective cohort study of 101 patients with mature T/NK-cell neoplasms (2008-2025). Survival (OS and PFS) was analyzed using Kaplan-Meier estimates and Cox models. Results: Median age was 58 years. PTCL-NOS (31.7%), anaplastic large cell lymphoma (20.8%), and extranodal NK/T-cell lymphoma (18.8%) were the most frequent subtypes. The 36-month OS was 57.8% and PFS was 42.1%. Significant prognostic heterogeneity was observed, with anaplastic large cell lymphoma showing the best and T-prolymphocytic leukemia the poorest outcomes. In multivariable analysis, ECOG status ≥2 independently predicted higher mortality (HR = 2.73, p<0.001), while low LDH levels reduced risk (HR: 0.22; 95% CI: 0.08-0.61; p = 0.003). Conclusions: These findings highlight the marked clinical heterogeneity of T-cell lymphomas and validate the prognostic value of ECOG and LDH in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.